文献速递流行病学与生物统计临床试验与 GCP

慢性阻塞性肺疾病筛查:美国预防服务工作组更新证据报告与系统综述

Screening for Chronic Obstructive Pulmonary Disease: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

该针对性系统综述更新了COPD筛查有效性与治疗证据,以支持USPSTF更新2016年推荐。未发现筛查有效性试验;药物治疗证据仍主要限于中度气流阻塞者,非药物治疗在轻度至中度或症状轻微者中无一致获益;观察性研究提示药物治疗存在心血管事件及糖尿病风险。

要点

  • 未发现评估COPD筛查有效性的试验。
  • 支气管扩张剂联合或不联合吸入糖皮质激素可减少中度COPD急性加重,噻托溴铵可改善健康相关生活质量。
  • 非药物治疗在轻度至中度或症状轻微COPD中无一致获益。

核心结论

  • 该针对性证据更新结果与先前系统综述基本一致,支持2016年USPSTF推荐。
  • 药物治疗证据仍主要限于中度气流阻塞者,非药物治疗在轻度至中度COPD或症状轻微者中无一致获益。

研究设计与样本

  • 针对性系统综述,检索MEDLINE、Cochrane对照试验中心注册库和CINAHL,纳入2015年1月1日至2021年1月22日发表的研究,监测至2022年3月25日。
  • 纳入不识别或不报告呼吸症状个体的筛查研究,以及轻度或中度或症状轻微COPD患者的治疗研究。
  • 两位评价者独立评估文献并提取 fair 或 good 质量研究的数据,未进行定量合成。

主要发现

  • 纳入筛查有效性试验0项;2015年以来发表的药物治疗试验或分析3项(n=20058);非药物干预试验13项(n=3657);药物治疗危害的大型观察性研究2项(n=243517)。
  • 药物治疗试验结果与先前综述一致,支持USPSTF:支气管扩张剂联合或不联合吸入糖皮质激素可减少中度COPD成人急性加重,噻托溴铵可改善健康相关生活质量。
  • 总体而言,任何类型非药物干预在一系列患者结局中均未观察到一致获益。
  • 报告不良事件的纳入治疗试验均未发现显著危害。
  • 两项在筛查相关人群中开展的大型观察性研究显示,治疗初治患者起始长效毒蕈碱拮抗剂或长效β激动剂与严重心血管事件风险相关,吸入糖皮质激素使用与发生糖尿病风险相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未发现评估筛查有效性的试验。
  • 药物治疗证据仍主要限于中度气流阻塞者。
  • 非药物干预在轻度至中度COPD或症状轻微者中未观察到一致获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the US. OBJECTIVE: To conduct a targeted systematic review to update the evidence on the effectiveness of screening for COPD and the treatment of COPD to inform the US Preventive Services Task Force (USPSTF) update of the 2016 recommendation statement on COPD screening. DATA SOURCES: MEDLINE, the Cochrane Central Register of Controlled Trials, and CINAHL for relevant studies published between January 1, 2015, to January 22, 2021; surveillance through March 25, 2022. STUDY SELECTION: English-language studies of screening in individuals who do not recognize or report respiratory symptoms; studies of treatment in persons with mild or moderate, or minimally symptomatic, COPD. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently appraised the articles and extracted relevant data from fair- or good-quality studies; no quantitative synthesis was conducted. MAIN OUTCOMES AND MEASURES: COPD-related morbidity or mortality, measures of health-related quality of life, and adverse events. RESULTS: The review included no trials on the effectiveness of screening, 3 trials or analyses (n = 20 058) of pharmacologic treatment published since 2015, 13 trials (n = 3657) on nonpharmacologic interventions, and 2 large observational studies (n = 243 517) addressing the harms of pharmacologic treatment published since 2015. The results from the clinical trials of pharmacologic therapy are consistent with the previous review supporting the USPSTF that bronchodilators with or without inhaled corticosteroids can reduce COPD exacerbations and tiotropium can improve health-related quality of life in adults with moderate COPD. Overall, there was no consistent benefit observed for any type of nonpharmacologic intervention across a range of patient outcomes. None of the included treatment trials that reported adverse effects found significant harms. Two large observational studies in a screen-relevant population demonstrated an association of the initiation of a long-acting muscarinic antagonist or long-acting beta agonist with the risk of a serious cardiovascular event in treatment-naïve patients and an association of inhaled corticosteroids use with the risk of developing diabetes. CONCLUSIONS AND RELEVANCE: The findings of this targeted evidence update are generally consistent with the findings of the previous systematic review supporting the 2016 USPSTF recommendation. Evidence of pharmacologic treatment was still largely limited to persons with moderate airflow obstruction, and there was no consistent benefit observed for a range of nonpharmacologic interventions in mild to moderate COPD or in minimally symptomatic persons with COPD.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Webber EM, Lin JS, Thomas RG, et al. Screening for Chronic Obstructive Pulmonary Disease: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35536261. doi:10.1001/jama.2022.4708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。